Inhibitors
- Newglycyl-L-histidyl-L-lysine [orb1089385]
[49557-75-7]
340.378162384033
C14H24N6O4
NCC(NC(C(NC(C(O)=O)CCCCN)=O)CC1N=CNC=1)=O
1 g, 5 g - NewTeplinovivint [orb1089386]
[1428064-91-8]
442.523
C25H26N6O2
O=C(C1C2=C(C=CC(=C2)C2=CN=CC(=C2)CN2CCCCC2)NN=1)NC1C=NC(=CC=1)OC
100 mg, 250 mg, 1 g - NewYKP-3089 [orb1089387]
[913088-80-9]
267.671700000763
C10H10CLN5O2
[C@H](C1C=CC=CC=1Cl)(OC(=O)N)CN1N=NC=N1
10 mM * 1 mL in DMSO, 100 mg, 250 mg, 1 g - NewCopper tripeptide [orb1089388]
[89030-95-5]
402.91622
C14H23N6O4-.CU+2
[Cu+2].NCCCC[C@@H](C(=O)[O-])NC(=O)[C@@H](NC(=O)CN)CC1NC=NC=1
100 mg, 250 mg - NewCPI-0610 [orb1089389]
[1380087-89-7]
365.812943458557
C20H16CLN3O2
ClC1=CC=C(C2=N[C@@]([H])(CC(O)=N)C3ON=C(C)C=3C3=CC=CC=C23)C=C1
100 mg, 250 mg, 1 g - NewPrezatide copper acetate [orb1089390]
[130120-57-9]
862.3904
C32H54CUN12O12
[Cu+2].O=C(C([H])(C([H])([H])C1=C([H])N=C([H])N1[H])N([H])C(C([H])([H])N([H])[H])=O)N([H])C([H])(C(=O)[O-])C([H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H].O=C(C([H])(C([H])([H])C1=C([H])N=C([H])N1[H])/N=C(/C([H])([H])N([H])[H])\[O-])N([H])C([H])(C(=O)[O-])C([H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H].O([H])C(C([H])([H])[H])=O.O([H])C(C([H])([H])[H])=O.[H+]
100 mg - NewLobaplatin(D-19466) [orb1089391]
[135558-11-1]
395.313
C9H18N2O3PT
CC1[O-][Pt]2(NCC3C(CC3)CN2)[O-]C1=O
100 mg, 250 mg, 1 g - NewSR-717 [orb1089392]
[2375420-34-9]
345.26
C15H9F2N5O3
O=C(O)C1=CC(F)=C(F)C=C1NC(C2=NN=C(N3C=CN=C3)C=C2)=O
100 mg, 250 mg, 1 g - NewFSLLRY-NH2 [orb1089393]
[245329-02-6]
796.95590877533
C39H60N10O8
NC(C(NC(C(NC(C(NC(C(NC(C(NC(C(N)=O)CC1C=CC(O)=CC=1)=O)CCCNC(=N)N)=O)CC(C)C)=O)CC(C)C)=O)CO)=O)CC1C=CC=CC=1
250 mg, 100 mg, 1 g - NewPF-05221304(Clesacostat) [orb1089394]
[1370448-25-1]
502.56
C28H30N4O5
O=C(O)C1=CC=C(C2=NC(OC)=CC(C(N3CCC(C4)(CC3)CC5=C(N(C(C)C)N=C5)C4=O)=O)=C2)C=C1
10 mM * 1 mL in DMSO, 100 mg, 250 mg, 1 g